TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers report that raising the enzyme Pla2g2f protected aging mice against several brain changes and memory impairment. Findings in human microglia and cognitively resilient older adults support further study, but the research does not establish a treatment for people.
Researchers report that increasing the brain enzyme Pla2g2f protected aging mice against several changes linked to cognitive decline, including memory impairment and loss of synapses. The study, published in Nature Neuroscience, also found that raising the enzyme’s activity reduced lipid-droplet buildup in human microglia grown for research, but it does not show that an enzyme-based treatment works in people.
The researchers identified Pla2g2f while looking for genes activated in response to synapse loss in the hippocampus, a brain region important for memory. The gene produces a secreted phospholipase, an enzyme whose role in the brain had not previously been established, according to the study. The team found that Pla2g2f levels rose in the hippocampus with aging and during brain inflammation.
To test its function, the scientists used genetic and viral methods to lower or raise Pla2g2f in the brains of aging mice. Lowering the enzyme was associated with more synapse loss and inflammation, disrupted lipid metabolism, impaired maturation of new brain cells, increased lipid droplets in neurons and microglia, and worse memory. Raising its levels protected against many of those effects and helped preserve memory.
The team also reported that boosting Pla2g2f in middle-aged mice before substantial cognitive decline changed the course of age-related memory loss. In experiments using human microglia, increased Pla2g2f activity reduced lipid droplets and cholesterol esters—features the researchers say are commonly observed in microglia in Alzheimer’s disease. Those laboratory findings are not evidence that the enzyme can prevent or treat Alzheimer’s in patients.
A Possible Route to Preserve Memory
The findings point to a biological process that may help the aging brain resist damage, rather than only tracking changes after they occur. Pla2g2f was linked to several systems implicated in brain aging, including synapse maintenance, inflammation and lipid handling. That breadth makes the enzyme a potential subject for further research into cognitive resilience.
The result matters because aging is a major risk factor for Alzheimer’s disease and other forms of cognitive impairment. However, the experiments do not establish that Pla2g2f can delay disease in humans, or that increasing it would be safe. Any future clinical relevance will depend on whether researchers can reproduce the effects and develop a way to alter enzyme activity without harmful side effects.
Products Worth Considering
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Fitbit Sense Health & Fitness Smartwatch (White/Gold, International Version)
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
As an affiliate, we earn on qualifying purchases.
How Researchers Found Pla2g2f
The work was led by Cinzia Vicidomini, PhD, and senior-authored by Amar Sahay, PhD, affiliated with Mass General Brigham’s Department of Psychiatry, the Harvard Stem Cell Institute and the Broad Institute of Harvard and MIT. Their paper, “An aging-sensitive secreted phospholipase confers neuroprotection and cognitive resilience,” appeared in Nature Neuroscience in 2026.
The research was motivated by evidence that aging can involve synapse loss, altered lipid metabolism and chronic inflammation. The study focused in part on lipid droplets inside microglia, immune cells in the brain. The researchers describe droplet buildup as a feature associated with microglia becoming less effective at clearing waste and supporting neurons. They examined whether a protective factor could counter some of these processes.
“We sought to identify the protective factors that contribute to cognitive resilience during aging.”
— Cinzia Vicidomini and Amar Sahay, the study’s lead and senior authors, in comments accompanying the report
Human Benefits Remain Unproven
The main evidence for memory protection comes from aging mice, while the human-cell experiments measured changes in microglia in laboratory conditions. The report does not establish whether Pla2g2f levels can be safely increased in a living human brain, whether doing so would preserve cognition, or whether it could prevent mild cognitive impairment or Alzheimer’s disease.
The source material does not provide details about clinical trials, a treatment method, dose, or timeline for testing patients. It also remains unclear how the enzyme’s activity affects different stages of aging and disease, and whether the findings will be replicated in further studies.
Testing Safe Ways to Raise Activity
The researchers say they are exploring approaches to safely increase Pla2g2f in the aging brain and in Alzheimer’s disease. The next steps will need to establish how the enzyme works, whether its protective effects can be reproduced, and what risks might come with changing its levels. Until those questions are addressed in further research, the findings should be viewed as an early-stage research direction rather than a treatment option.
Key Questions
What is Pla2g2f?
Pla2g2f is a gene that produces a secreted phospholipase enzyme. Researchers found that its levels increased in the hippocampus during aging and brain inflammation, and they tested its effects in mice and human microglia grown for research.
Did the enzyme prevent memory loss in people?
No human treatment effect was established. The reported memory findings came from aging mice; the human-related experiments examined microglia in a laboratory setting.
What happened when researchers increased Pla2g2f in mice?
Raising Pla2g2f protected against several measured features of brain aging and helped preserve memory. The researchers also reported that boosting it in middle-aged mice before substantial cognitive decline changed the trajectory of age-related memory loss.
Could Pla2g2f become an Alzheimer’s treatment?
It is a possible research direction, not an available or proven treatment. The authors say further studies are needed to determine whether increasing Pla2g2f can be done safely and translated into therapies for patients.
Source: rss
